Integrin-Targeting Transformable Nanomedicine for Treatment of Non-Small Cell Lung Cancer
Abstract
The objective of this project is to develop novel and highly effective nanotherapeutic agents for treatment of non-small cell lung cancer via increasing tumor-specific targeting and therapeutic effect of chemotherapy, while reducing systemic toxicity. This nanoplatform involves two-component, two-step, intravenous administration. After injection, component 1, which is a nanoparticle, will bind to a protein, named ?3?1 integrin, on the tumor cell surface and enriched at the tumor site, transformed from the nanoparticle to the nanofibrillar network. After clearance of nanofibrils/nanoparticles from normal organs in a couple of days, the second component, which is a chemodrug conjugated with a chemical that can efficiently linked to the surface of the nanofibril at the tumor sites, can be administered, resulting in slow drug release to kill the cancer cells. In this proposal, we will prepare and characterize those smart transformable nanoparticles and evaluate their toxicity and anti-cancer effect in mice bearing non-small cell lung cancer tumors. If successful, the novel nanomedicine to be developed in this application could provide an innovative strategy for treatment of non-small cell lung cancer and benefit patients including military Service Members, Veterans, and their family members.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jan 04, 2024
- Source ID
- HT94252310358
Entities
People
- Ruiwu Liu
Organizations
- United States Army
- University of California, Davis